Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Ferring announces drug approval

Ferring announces drug approval

30th December 2008

Ferring has announced its degarelix drug has received approval.

The gonadotropin-releasing hormone (GnRH) receptor antagonist can be delivered via vaccine and is to be used as a treatment for patients with advanced prostate cancer.

The drug’s endorsement follows the Committee for Medicinal Products for Human Use decision on December 18th, which said the product could be marketed in Europe.

It is, however, awaiting approval in other markets and potential trade names are also under review.

The endorsement follows phase III studies, which found 96 per cent of patients taking the product reached castrate levels of testosterone, in comparison to zero per cent taking leuprolide.

Furthermore, it was found the product is as effective as the drug, also known as Lupron Depot, in sustaining such amounts of the hormone.

Dr Pascal Danglas, executive vice-president of clinical and product development at Ferring, said: “In its pivotal phase III study, [degarelix] demonstrated both an immediate onset of action and a profound long-term suppression of testosterone.

“We are delighted to deliver a new treatment option for advanced prostate cancer.”

Formed in the UK in 1975, Ferring currently specialises in gastroenterology and hepatology, urology and continence, reproductive health and paediatric endocrinology.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.